AARD
MaterialsAardvark Therapeutics Inc
$5.89+0.42 (+7.68%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving AARD Today?
No stock-specific AI insight has been generated for AARD yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$128M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume137K
Avg Volume (10D)—
Shares Outstanding21.8M
AARD News
21 articles- Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesYahoo Finance·May 7, 2026
- Discover 3 Promising Penny Stocks With Market Caps Over $100MYahoo Finance·Apr 17, 2026
- Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens BermanGlobeNewswire Inc.·Apr 9, 2026
- Why Aardvark Therapeutics (AARD) Paused Late-Stage ARD-101 Trials After Cardiac FindingsYahoo Finance·Mar 29, 2026
- Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesYahoo Finance·Mar 23, 2026
- A Look At Aardvark Therapeutics (AARD) Valuation After The Voluntary Pause Of Its Phase 3 HERO TrialYahoo Finance·Mar 5, 2026
- Aardvark Therapeutics (AARD) Is Down 61.4% After Pausing Phase 3 HERO Trial Over Cardiac Safety QuestionsYahoo Finance·Mar 4, 2026
- Why Aardvark Therapeutics Just Lost More Than Half Its ValueYahoo Finance·Mar 2, 2026
- Sector Update: Health Care Stocks Retreat Late AfternoonYahoo Finance·Mar 2, 2026
- Safety concerns spur Aardvark to halt key Prader-Willi drug trialBiopharmadive·Mar 2, 2026
- Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi SyndromeYahoo Finance·Feb 27, 2026
- Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Feb 13, 2026
- Aardvark Therapeutics Announces Leadership AppointmentsYahoo Finance·Feb 12, 2026
- Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive OfficerYahoo Finance·Feb 12, 2026
- Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi SyndromeYahoo Finance·Feb 10, 2026
- Aardvark Therapeutics, Inc. (NASDAQ:AARD) stock most popular amongst retail investors who own 32%, while private equity firms hold 28%Yahoo Finance·Jan 19, 2026
- Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst callsYahoo Finance·Dec 23, 2025
- Rhythm Pharma Hits Record High On Unexpected Obesity-Tied WinYahoo Finance·Dec 11, 2025
- Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi SyndromeYahoo Finance·Dec 10, 2025
- Aardvark Therapeutics to Present at Upcoming Investor Conferences in DecemberYahoo Finance·Nov 25, 2025
- Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business UpdatesYahoo Finance·Nov 13, 2025
All 21 articles loaded
Price Data
Open$0.00
Previous Close$5.47
Day High$0.00
Day Low$0.00
52 Week High—
52 Week Low—
Fundamentals
Market Cap$128M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume137K
Avg Volume (10D)—
Shares Outstanding21.8M
About Aardvark Therapeutics Inc
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—